Management

Petter Segelman Lindqvist has a MSc in Business and Economics from the Stockholm School of Economics, Sweden, and EM Lyon, France. He has experiences from leading positions in the pharmaceutical industry, including within GlaxoSmithKline, AbbVie and Sobi (Swedish Orphan Biovitrum), as well as from board work in smaller biotech companies. He joined the company in 2024 and contributes with knowledge of strategic business development and partnerships, global commercialization, and product development. He has led several product launches and has taken drug candidates through clinical development and regulatory processes to market introduction.

Holidings*:
579,663 shares, 171,444 warrants serie TO1, 171,444 warrants serie TO2, 963 036 performance-based share rights 2025-2028

Contact
petter.s.lindqvist@isofolmedical.com

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2025.

Roger Tell is responsible for medical and scientific issues at Isofol. Dr. Tell joined Isofol in 2019 as Senior Vice President of Clinical Development, Chief Scientific Officer and Chief Medical Officer. He has also been acting CEO for a period. He joined Isofol from Aprea Therapeutics, where he was Vice President of Clinical Development. Prior to Aprea, he was an International Clinical Project Director at Servier in Paris, France. He has an extensive experience as an oncologist as well as an advisor to a number of biopharma companies, including Eli Lilly, Astra Zeneca and Merck Serono. He is board member in Vivesto which is listed on Nasdaq Stockholm. Dr. Tell holds a medical degree and a doctorate in experimental oncology from the Karolinska Institutet in Sweden, and he completed his residency in oncology at the Karolinska University Hospital.

Holidings*:
60,000 shares, 20,000 warrants serie TO1, 20,000 warrants serie TO2, 258 971 performance-based share rights 2025-2028

Contact
roger.tell@isofolmedical.com

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2025.

Margareta Hagman holds an M.Sc. in Finance from Örebro University, Sweden. She has long experience from CFO roles and other positions in both listed and unlisted companies within the pharmaceutical and biotech industry. Notably, she has been the Executive Vice President and Chief Financial Officer (CFO) at BioGaia AB. Margareta has also been the CFO at Xbrane Biopharma AB and Ortivus AB and is a board member at Infant Bacterial Therapeutics AB – all companies listed on Nasdaq Stockholm. Margareta Hagman joined the company in 2024.

Holidings*:
126,664 shares, 28,888 warrants serie TO1, 28,888 warrants serie TO2, 178 773 performance-based share rights 2025-2028

Contact
margareta.hagman@isofolmedical.com

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of December 31, 2025.